Roche Diagnostics (Indianapolis) has received FDA clearance for what the company says is the first and only natriuretic peptide test to be green-lighted by the FDA for risk assessment of cardiac events in people with stable coronary artery disease. The company said that nearly 13 million people in the U.S. have stable coronary artery disease, making them more susceptible than the general population for the development of adverse cardiac events.